Vyriad
Manufacturing · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2900 37th St NW Bldg 110, Rochester, Min...Phone Number
(507) 289-0944Website
www.vyriad.comRevenue
$19 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Vyriad
Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence. Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabiRead more
Vyriad Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vyriad your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Vyriad is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Vyriad launches new products
Click to see if Vyriad had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Vyriad has new funding data
Vyriad, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Vyriad has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Vyriad
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Vyriad recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Vyriad
Compare insights from companies similar to Vyriad, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$114.2M
51-200
Public
$462.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Vyriad is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vyriad is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vyriad.
Vyriad financials insights
Gather financial insights about Vyriad, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$10M
2025
Series B
$85M
Vyriad Tech Stack
A closer look at the technologies used by Vyriad
See more technologies
Most Recent Scoops
Person-Based
Product Launch, Medical Research
Event
Product Marketing, Events, Sales, Search, Laboratory Operations, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Open Position
Person-Based
Funding
Funding
Vyriad News & Media
Vyriad Raises $25M Series B Round
ROCHESTER, MN, Vyriad has announced the closing of the $25 million final tranche to its Series B financing.Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies
Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic...Vyriad Announces Oral Presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting
ROCHESTER, Minn., May 6, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears...Rochester's Vyriad lands a new $29.5 million round of investment
May 17—ROCHESTER — An Iowa entrepreneur known for his work in agriculture recently invested $29.5 million in a growing Med City biotechnology firm. The investment by Stine Seed Farms, Inc., led by billionaire Harry Stine, adds to Series B round of funding for Vyriad, Inc. Vyriad, founded in 2016 by Mayo Clinic researchers Dr. Kah-Whye Peng and Dr. Stephen Russell, uses viruses, such as measles ...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vyriad
Sign Up For FreeTo access detailed company insights
Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to... Read More
